Rotarix®

BIOLOGICAL3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), GlaxoSmithKline, Centre for Infectious Disease Research in Zambia

Conditions

DiarrheaDiarrhea RotavirusHaemophilus Influenzae Type bNeisseria MeningitidisRotavirus Infection

Phase 2

Study of BBIL's ROTAVAC® and ROTAVAC 5CM Vaccines in Zambia

CompletedNCT03602053

Centre for Infectious Disease Research in ZambiaDiarrhea, Diarrhea Rotavirus

Start: 2019-01-22End: 2019-10-04Updated: 2020-12-19

Phase 3

Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age

CompletedNCT01978093

GlaxoSmithKlineHaemophilus Influenzae Type b, Neisseria Meningitidis

Start: 2014-02-01End: 2016-03-18Updated: 2018-09-14

Phase 4

Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules

CompletedNCT01266850

National Institute of Allergy and Infectious Diseases (NIAID)Rotavirus Infection

Start: 2011-03-31End: 2014-03-31Updated: 2014-10-28

Related Papers

2280. Antibiotic Exposure Does Not Impact Serological Responses to Rotavirus Vaccination

Open Forum Infectious Diseases2018-11-01

Immunogenicity and safety of the <i>Haemophilus influenzae</i> type b and <i>Neisseria meningitidis</i> serogroups C and Y-tetanus toxoid conjugate vaccine co-administered with human rotavirus, hepatitis A and 13-valent pneumococcal conjugate vaccines: results from a phase III, randomized, multicenter study in infants

Human Vaccines & Immunotherapeutics2018-09-254 citations